Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HINT1 | P49773 | 5/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744361 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12031119 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16198946 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12150640 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12300426 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16360143 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL3713950 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL26515 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL18512866 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| Water SCHEMBL25345533 | 0.99 | HPGD (0.60) | HPGDHINT1NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2684 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260053941-A1 | MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | claimed |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | claimed |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | claimed |
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | claimed |
| WO-2007130783-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20050037394-A1 | preparing transcription reaction mixture comprising mutated polymerase, modified nucleotide triphosphates (NTPs), magnesium ions and oligonucleotide templates, partitioning high affinity nucleic acids, then replicating; point mutations; increased stability and half life | ARCHEMIX CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20040197804-A1 | Method for in vitro selection of 2'-substituted nucleic acids | ARCHEMIX CORPORATION | 2004-10-07 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| US-6495675-B1 | BINDS PB2 PROTEIN OF RNA POLYMERASE | CHIBA INSTITUTE OF TECHNOLOGY (JP) | 2002-12-17 | — | — | US | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-5962675-A | Chemical syntheses of 2'-O-methoxy purine nucleosides | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | claimed |